ECSP22044316A - Mol?culas de fusi?n del ecd de siglec-9 y m?todos de uso de estas - Google Patents
Mol?culas de fusi?n del ecd de siglec-9 y m?todos de uso de estasInfo
- Publication number
- ECSP22044316A ECSP22044316A ECSENADI202244316A ECDI202244316A ECSP22044316A EC SP22044316 A ECSP22044316 A EC SP22044316A EC SENADI202244316 A ECSENADI202244316 A EC SENADI202244316A EC DI202244316 A ECDI202244316 A EC DI202244316A EC SP22044316 A ECSP22044316 A EC SP22044316A
- Authority
- EC
- Ecuador
- Prior art keywords
- siglec
- fusion molecules
- methods
- ecd
- ecd fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Recrystallisation Techniques (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente descripci?n se refiere generalmente al ECD de Siglec-9 o mol?culas de fusi?n del ECD de Siglec-9, y a m?todos de tratamiento que usan ECD de Siglec-9 y mol?culas de fusi?n del ECD de Siglec-9.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962930227P | 2019-11-04 | 2019-11-04 | |
US202063014940P | 2020-04-24 | 2020-04-24 | |
US202063092753P | 2020-10-16 | 2020-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22044316A true ECSP22044316A (es) | 2022-07-29 |
Family
ID=73598983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202244316A ECSP22044316A (es) | 2019-11-04 | 2022-06-02 | Mol?culas de fusi?n del ecd de siglec-9 y m?todos de uso de estas |
Country Status (17)
Country | Link |
---|---|
US (1) | US11987612B2 (es) |
EP (1) | EP4055031A2 (es) |
JP (1) | JP2022553571A (es) |
KR (1) | KR20220092918A (es) |
CN (1) | CN114667298A (es) |
AU (1) | AU2020378251A1 (es) |
BR (1) | BR112022008321A2 (es) |
CA (1) | CA3155345A1 (es) |
CL (1) | CL2022001130A1 (es) |
CO (1) | CO2022005587A2 (es) |
CR (1) | CR20220244A (es) |
EC (1) | ECSP22044316A (es) |
IL (1) | IL292499A (es) |
MX (1) | MX2022005376A (es) |
PE (1) | PE20221271A1 (es) |
TW (1) | TW202132329A (es) |
WO (1) | WO2021091885A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021214019A1 (en) | 2020-04-24 | 2021-10-28 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
WO2024102635A1 (en) * | 2022-11-07 | 2024-05-16 | Alector Llc | Uses of siglec-9 ecd fusion molecules in cancer treatment |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
EP1556684A4 (en) | 2002-11-01 | 2008-01-23 | Univ Colorado Regents | QUANTITATIVE ANALYSIS OF PROTEIN ISOFORMS USING FLIGHT TIME MASS SPECTROMETRY BY MATRIX ASSISTED LASER DESORPTION / IONIZATION |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
GB0521991D0 (en) | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
WO2007120815A2 (en) | 2006-04-12 | 2007-10-25 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind B7-H1 and PD-1 |
RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
CA2859785A1 (en) | 2011-12-21 | 2013-06-27 | Amgen Inc. | Variant fc-polypeptides with enhanced binding to the neonatal fc receptor |
JP6403062B2 (ja) | 2012-12-21 | 2018-10-10 | 国立大学法人徳島大学 | 組織修復活性組成物及びその利用 |
WO2014120642A1 (en) | 2013-01-30 | 2014-08-07 | The General Hospital Corporation | Diagnosis and treatment of hepatorenal syndrome |
EP3191517B1 (en) | 2014-09-10 | 2020-11-04 | Innate Pharma | Cross reactive siglec antibodies |
CA3155251A1 (en) | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
CN116003596A (zh) * | 2015-10-29 | 2023-04-25 | 艾利妥 | 抗siglec-9抗体及其使用方法 |
CN108351337B (zh) | 2015-10-30 | 2021-01-12 | 哈希公司 | 用于含水氯分析的储存稳定的标准物 |
US11083785B2 (en) * | 2015-11-17 | 2021-08-10 | Innate Pharma | Siglec-10 antibodies |
WO2017123745A1 (en) | 2016-01-12 | 2017-07-20 | Palleon Pharma Inc. | Use of siglec-7 or siglec-9 antibodies for the treatment of cancer |
US11078274B2 (en) | 2016-03-08 | 2021-08-03 | Innate Pharma | Siglec neutralizing antibodies |
GB201611535D0 (en) | 2016-07-01 | 2016-08-17 | King's College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
CA3026588A1 (en) | 2016-07-01 | 2018-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitory immune receptor inhibition methods and compositions |
US11447545B2 (en) | 2017-07-10 | 2022-09-20 | Innate Pharma | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer |
CA3066514A1 (en) | 2017-07-10 | 2019-01-17 | Innate Pharma | Siglec-9-neutralizing antibodies |
CA3101988A1 (en) | 2018-06-07 | 2019-12-12 | Palleon Pharmaceuticals Inc. | Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder |
JP2021529753A (ja) | 2018-06-29 | 2021-11-04 | ヴェルソー セラピューティクス, インコーポレイテッド | 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法 |
CN112805032A (zh) | 2018-10-02 | 2021-05-14 | 台湾浩鼎生技股份有限公司 | 与治疗性肿瘤学药剂组合使用抗ssea-4抗体的组合疗法 |
US20220211831A1 (en) | 2019-04-17 | 2022-07-07 | Bar-Ilan University | Siglec-based chimeric polypeptides and uses thereof |
CN114401991A (zh) | 2019-06-04 | 2022-04-26 | 维西欧制药公司 | 用于调节髓系细胞炎性表型的抗siglec-9组合物和方法及其用途 |
WO2021011377A2 (en) | 2019-07-12 | 2021-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of enhancing immunogenicity of cancers |
-
2020
- 2020-11-03 WO PCT/US2020/058687 patent/WO2021091885A2/en unknown
- 2020-11-03 PE PE2022000710A patent/PE20221271A1/es unknown
- 2020-11-03 EP EP20816024.2A patent/EP4055031A2/en active Pending
- 2020-11-03 BR BR112022008321A patent/BR112022008321A2/pt unknown
- 2020-11-03 KR KR1020227017802A patent/KR20220092918A/ko unknown
- 2020-11-03 MX MX2022005376A patent/MX2022005376A/es unknown
- 2020-11-03 US US17/088,149 patent/US11987612B2/en active Active
- 2020-11-03 CA CA3155345A patent/CA3155345A1/en active Pending
- 2020-11-03 CN CN202080076354.8A patent/CN114667298A/zh active Pending
- 2020-11-03 CR CR20220244A patent/CR20220244A/es unknown
- 2020-11-03 JP JP2022524955A patent/JP2022553571A/ja active Pending
- 2020-11-03 TW TW109138156A patent/TW202132329A/zh unknown
- 2020-11-03 AU AU2020378251A patent/AU2020378251A1/en active Pending
-
2022
- 2022-04-25 IL IL292499A patent/IL292499A/en unknown
- 2022-04-29 CO CONC2022/0005587A patent/CO2022005587A2/es unknown
- 2022-05-02 CL CL2022001130A patent/CL2022001130A1/es unknown
- 2022-06-02 EC ECSENADI202244316A patent/ECSP22044316A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020378251A1 (en) | 2022-05-26 |
WO2021091885A3 (en) | 2021-06-17 |
EP4055031A2 (en) | 2022-09-14 |
MX2022005376A (es) | 2022-05-19 |
IL292499A (en) | 2022-06-01 |
KR20220092918A (ko) | 2022-07-04 |
CR20220244A (es) | 2022-06-28 |
TW202132329A (zh) | 2021-09-01 |
CO2022005587A2 (es) | 2022-07-29 |
US11987612B2 (en) | 2024-05-21 |
BR112022008321A2 (pt) | 2022-07-26 |
CN114667298A (zh) | 2022-06-24 |
JP2022553571A (ja) | 2022-12-23 |
PE20221271A1 (es) | 2022-09-01 |
WO2021091885A2 (en) | 2021-05-14 |
US20210284710A1 (en) | 2021-09-16 |
CL2022001130A1 (es) | 2023-02-24 |
CA3155345A1 (en) | 2021-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
CL2019002824A1 (es) | Anticuerpos anti-lag3. | |
DOP2020000021A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39 | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
NI201800055A (es) | Anticuerpos que se unen específicamente a pd-1 y sus usos. | |
ECSP22044316A (es) | Mol?culas de fusi?n del ecd de siglec-9 y m?todos de uso de estas | |
GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
EA201792613A1 (ru) | Модуляторы cot и способы их применения | |
EA201791775A1 (ru) | Цистеиновая протеаза | |
BR112017020952A2 (pt) | método de tratamento de câncer, composição e uso da composição | |
CL2018003527A1 (es) | Conjugados de anticuerpo anti-egfr y fármaco. | |
CL2023001550A1 (es) | Sistemas activos dinámicos acromosómicos. | |
BR112018074032A2 (pt) | composições e métodos relacionados a construtos de fc manipulados | |
BR112019002646A2 (pt) | composições de poxvírus quimérico e usos das mesmas | |
BR112017001162A2 (pt) | métodos para tratar paramixovírus | |
BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
CO2018005393A2 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos | |
BR112017013111A2 (pt) | métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo | |
BR112019005139A2 (pt) | anticorpos anti-il-33 e usos dos mesmos | |
BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
CL2016002827A1 (es) | Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos. | |
BR112021014944A2 (pt) | Toxinas apxia, apxiia e apxiiia inativas | |
BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
BR112017020896A2 (pt) | variantes de protoxina-ii e métodos de uso | |
BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo |